Experimental Treatment of Human Hodgkin's Disease with Ricin A-Chain Immunotoxins

References

• Vitetta E. S., Stone M., Amlot P., Fay J., Till M., Uhr J. W. Redesigning nature's poisons to create antitumor agents. Science 1987; 238: 1098–1104
   PubMed Web of Science ®Google Scholar
• Fitz Gerald D., Pastan I. Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst. 1989; 81: 1455–1462
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Richardson J., Tucker T., Jones D., Uhr J., Vitetta E. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res. 1991; 51: 5876–5860
   PubMed Web of Science ®Google Scholar
• Jansen B., Vallera D., Jaszcz W., Nguyen D., Kersey J. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res. 1992; 52: 1314
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Detre S. I., Foxwell B. M. J., Brown A. N. F., Skilleter D. N., Wilson G., Forrester J. A., Stirpe F. Modification of the carbohydrate in ricin with me-taperiodate-cyanoborohydride mixtures. Effect on toxicity and in vivo distribution. Eur. J. Biochem. 1985; 147: 197
   PubMedGoogle Scholar
• Blakey D. C., Watson G., Knowles P. P., Thorpe P. E. Effect of chemical deglycosilation of ricin A-chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A-chain and anti-Thy 1.1 antibody. Cancer Res. 1987; 47: 947–952
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N. F., Watson G. J., Knyba R. E., Wawrzyn-Czak E. J., Blakey D. C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 1987; 47: 5924–5931
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N. F., Watson G. J., Blakey D. C., Newell D. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disul fide linkages. Cancer Res. 1988; 48: 6396
   PubMed Web of Science ®Google Scholar
• Knowles P. P., Thorpe P. E. Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Anal. Biochem. 1987; 160: 440–443
   PubMed Web of Science ®Google Scholar
• Kaplan H. S. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer 1980; 45: 2439
   PubMed Web of Science ®Google Scholar
• Diehl V., Kirchner H. H., Schaadt M., Fonatsch C., Stein H., Gerdes J., Boie C. Hodgkin's Disease: Establishment and characterization of four in vitro cell lines. J. Cancer Res. Clin. Oncol. 1981; 101: 111
   PubMed Web of Science ®Google Scholar
• Till M., May R. D., Uhr J. W., Thorpe P. E., Vitetta E. S. An assay that predicts the ability of monoclonal antibodies to form potent ricin A-chain-containing immunotoxins. Cancer Res. 1988; 48: 1119
   PubMed Web of Science ®Google Scholar
• Hsu S.-M., Ho Y.-S., Hsu P.-L. Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HcFi-1 on the surface antigens of Reed-Sternberg cells. J. Natl. Cancer Inst. 1987; 79: 1091–1097
   PubMed Web of Science ®Google Scholar
• Engert A., Burrows F., Jung W., Tazzari P. L., Stein H., Pfreundschuh M., Diehl V., Thorpe P. E. Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin's disease. Cancer Res. 1990; 50: 84–88
   PubMed Web of Science ®Google Scholar
• Engert A., Martin G., Pfreundschuh M., Amlot P., Hsu S. M., Diehl V., Thorpe P. E. Antitumor effects of ricin A-chain immunotoxins from intact antibodies and Fab'fragments on solid human Hodgkin's disease tumors in mice. Cancer Res. 1990; 50: 2929–2935
   PubMed Web of Science ®Google Scholar
• Engert A., Martin G., Pfreundschuh M., Amlot P., Wijdenes J., Diehl V., Thorpe P. E. Immunotoxins constructed with CD25 monoclonal antibodies and de-glycosilated ricin A-chain have potent antitumor effects against human Hodgkin's cells in vitro and solid Hodgkin tumors in mice. Int. J. Cancer 1991; 49: 450–456
   PubMed Web of Science ®Google Scholar
• Winkler U., Gottstein C., Schon G., Kapp U., Wolf J., Diehl V., Thorpe P. E., Engert A. Successful treatment of disseminated Hodgkin's lymphoma in SCID mice with two ricin A-chain immunotoxins against H-RS cells. Blood 1993, in press
   Google Scholar
• Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's Disease. Anal. Oncol. 1992; 3(Suppl. 4)117–128
   PubMedGoogle Scholar
• Kreuser E. D., Felsenberg D., Behles C. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Anal. Oncol. 1992; 3(Suppl. 4)105–110
   PubMedGoogle Scholar
• Valagussa P., Santoro A., Bonadonna G. Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease. Anal. Oncol. 1992; 3(Suppl. 4)111–116
   PubMedGoogle Scholar
• Falini B., Bolognesi B. A., Flenghi L., Tazzari P. L., Broe M. K., Stein H., Diirkop H., Aversa F., Corneli P., Pizzolo G., Barbabielola G., Sabattini E., Pileri S., Mar-Telli M. F., Stirpe F. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195–1196
   PubMed Web of Science ®Google Scholar
• Woodworm T. G., Le Maistre C. F., McCaffrey R., Schnipper L., Rosen S., Ratain M. Phase I/II clinical studies of DAB486IL-2 fusion toxin in patients with refractory IL-2 receptor expressing malignancies. Blood 1992; 80(Suppl. 1)158A
   Google Scholar
• Conry R. M., Khazaeli M. B., Sumerel L., Saleh M., Ghetie V., Thorpe P. E., Uhr J. W., Vitetta E. S., Lo Buglio A. F. A phase I study of murine monoclonal antibody HD37-deglycosylated ricin A-chain in chemotherapy resistant B cell lymphoma. Blood 1992; 80(Suppl. 1)44A
   Google Scholar
• Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham P., Ghetie V., Uhr J. W., Thorpe P. E. Phase-I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991; 51: 4052–4058
   PubMed Web of Science ®Google Scholar
• Roy D. C., Robertson M. J., Belanger R., Gyger M., Per-Reault C, Bonny Y., Soiffer R., Epstein C., Ritz J. Engraftment following anti-MY9-bR depleted autologous transplantation for patients with acute myeloid leukemia. Blood 1992; 80: 376A
   Google Scholar